由于分子生物学的发展,基因操作技术的进步,特别是肿瘤特异性抗原的确定,持续了近百年的肿瘤免疫治疗,特别是主动免疫治疗,近几年有了突破性进展。目前,肿瘤的主动免疫治疗,更确切地说应该是肿瘤的免疫基因治疗,已推进到III期临床实验,给患者带来了切实的好处,使患者有了新的希望。相信在不久的将来,肿瘤的主动免疫基因治疗的研究与应用,将在我国蓬勃发展起来。 Due to the development of molecular biology, advances in gene manipulation technology, and in particular the determination of tumor-specific antigens, have continued for almost a hundred years of tumor immunotherapy, particularly active immunotherapy, and there have been breakthroughs in recent years. At present, active immunotherapy of tumors, more precisely tumor immune gene therapy, has advanced to phase III clinical trials, bringing real benefits to patients and giving patients new hope. It is believed that in the near future, the research and application of active immune gene therapy for tumors will flourish in China.